Alzheimer's Disease variant portal (ADVP): a catalog of genetic findings for Alzheimer's Disease

Pavel P. Kuksa, PhD[1,2,*]; Chia-Lun Liu, PhD[1,2,*]; Wei Fu, PhD[1,2,*]; Liming Qu, MS[1,2]; Yi Zhao, MS[1,2]; Zivadin Katanic, BS[1,2]; Amanda B Kuzma, MS[1,2]; Pei-Chuan Ho, MS[4]; Kai-Teh Tzeng, MS[4]; Otto Valladares, BS[1,2]; Shin-Yi Chou, PhD[1,2,4]; Adam C Naj, PhD[1,3]; Gerard D Schellenberg, PhD[1,2]; Li-San Wang, PhD[1,2,^]; and Yuk Yee Leung, PhD[1,2,^]

[1]*Penn Neurodegeneration Genomics Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA, USA*

[2] *Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA, USA*

[3] *Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA, USA*

[4] *Department of Economics, Lehigh University, Bethlehem, PA, USA*

* co-first author

^ co-corresponding author

Corresponding author information:

Li-San Wang, PhD.

Mailing address: Richards Building, D101, 3700 Hamilton Walk, Philadelphia, PA 19104

Phone: 215-746-7015

Fax: 215-573-3111

Email: lswang@pennmedicine.upenn.edu

Yuk Yee Leung, PhD.

Mailing address: Richards Building, D102, 3700 Hamilton Walk, Philadelphia, PA 19104

Phone: 215-573-3729

Fax: 215-573-3111

Email: yyee@pennmedicine.upenn.edu

Abstract

Alzheimer's Disease (AD) genetics has made substantial progress through genome-wide association studies (GWASs). An up-to-date resource providing harmonized, searchable information on AD genetic variants with linking to genes and supporting functional evidence is needed.

We developed the Alzheimer's Disease Variant Portal (ADVP), an extensive collection of associations curated from >200 GWAS publications from Alzheimer's Disease Genetics Consortium (ADGC) and other researchers. Publications are reviewed systematically to extract top associations for harmonization and genomic annotation.

ADVP V1.0 catalogs 6,990 associations with disease-risk, expression quantitative traits, endophenotypes and neuropathology across >900 loci, >1,800 variants, >80 cohorts, and 8 populations. ADVP integrates with NIAGADS Alzheimer's GenomicsDB where investigators can cross-reference other functional evidence.

ADVP is a valuable resource for investigators to quickly and systematically explore high-confidence AD genetic findings and provides insights into population- and tissue-specific AD genetic architecture. ADVP is continually maintained and enhanced by NIAGADS and is freely accessible (https://advp.niagads.org).

1. Introduction

Alzheimer's Disease (AD) is a devastating neurological disorder affecting millions of people worldwide and is the most common cause of dementia [1]. There are no approved drugs that can slow or treat the disease. The disease is complex and highly heritable [2]. The strongest known genetic risk factor for AD is the ε4 allele of the Apolipoprotein E gene (*APOE* ε4) [3,4], but more than one-third of AD cases do not carry any *APOE* ε4 alleles. Large-scale genome-wide association studies (GWASs) have led to the discovery of additional common genetic loci associated with the late-onset AD (LOAD) [5–9]. Yet, the identification of genetic contributors to LOAD remains a challenge as LOAD is likely caused by multiple low penetrance genetic variants [10], with the small sample sizes further complicating the identification of these causal variants.

The Alzheimer's Disease Genetics Consortium (ADGC) was founded in 2009 and funded by National Institute on Aging (NIA), to conduct large sample GWAS to identify genes associated with an increased risk of developing LOAD. ADGC co-founded IGAP (International Genomics of Alzheimer's Project) with three other AD genetics consortia: Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the European Alzheimer's Disease Initiative (EADI), and the Genetic and Environmental Risk in Alzheimer's Disease (GERAD) Consortium. IGAP assembled large Caucasian samples for better statistical power and was able to identify 19 genome-wide significant loci in 2013 [11], and five more loci using more than 30,000 samples in 2019 [12].

In addition to GWA studies focused on association with disease risk, recently many

genetics studies have focused on related phenotypes including neuroimaging

biomarkers [13], circulating biomarkers in [14,15], cognitive decline [16,17]

neuropathology [18], family history [19]. GWAS on Hispanic, African-American, Asian,

and other minority populations also led to new variants not observed in Caucasians [20–

22] In order to help investigators better explore the rich and diverse literature of genetic

findings, it is important to have a single resource with harmonized, unified, searchable

information on identified genetic variants and genes across a variety of AD studies and

populations, along with supporting functional genomic evidence.

To meet this need, we have cataloged genetic association results (both genome-wide

significant associations [$p \leq 5\text{x}10^{-8}$ by convention] and all other associations highlighted

in the main text from all major GWA studies published by ADGC from 2009 to 2019 and

other AD GWAS articles identified from the NHGRI/EBI GWAS Catalog (Buniello et al.,

2019). Summaries extracted from each of the articles are made publicly available on a

continuously updated and freely accessible Alzheimer's Disease Variant Portal (ADVP)

(https://advp.niagads.org). To date, ADVP provides the largest, most updated, and

comprehensive collection of systematically curated, harmonized, and annotated AD-

specific genetic associations. This first release contains information on 6,990 genetic

associations, >900 genomic loci curated from >125 AD publications categorized into

nine harmonized phenotype categories. All AD associations in ADVP are annotated with

genomic and functional information. Comprehensive biological annotations are available

via integration with the NIAGADS Alzheimer's Disease Genomics database [24]. ADVP

will serve as an invaluable resource for the research community to explore and decipher

the genetic architecture of AD and other neurodegenerative diseases.

2. Methods

An overview of the ADVP study design is shown in **Figure 1**.

2.1 Collection and curation of AD-related GWAS publications (Data

collection)

This ADVP V1.0 release consists of curated and harmonized genetic associations from

the genome-wide significant and suggestive loci collected from AD genetic studies

conducted primarily by the ADGC. All AD GWAS publications by ADGC (2009-2019,

http://www.adgenetics.org) and all other AD GWA studies in GWAS catalog [23] (MeSH

D000544, curation date: Dec 2019) were included. All the publications (total N=205;

ADGC: N=134; Citations from ADGC: N=20; GWAS catalog: N=51) were first screened

to identify publications reporting GWAS findings. For each publication, all main genetic

associations reported in the main text (table format) were systematically extracted. As

the current ADVP release focuses on the major/main findings in each publication/GWA

study, we did not extract associations reported in the supplementary tables as they

often represent supplemental findings not reaching the same kind of statistical

significance as the main associations. In total, we curated the 125 publications which

contain GWAS findings in the main text (https://advp.niagads.org/publications).

Supplementary Table S1 provides details on all curated AD publications in ADVP

V1.0. Note the ADGC family-based analyses results will be included in the next release.

2.2 Extraction of genetic variants and associations from publications (Data extraction)

We applied the following systematic data extraction and curation procedure for each publication to organize all the extracted variant and association information into a structured tabular format according to the ADVP data schema (see Section "**2.3 Meta-data design**" for details about the columns). In each publication, we identified all the tables in the main text with reported association p-values. All the information for these associations was then saved into a standardized template document using the corresponding meta-data schema and the two predefined worksheets: publication meta-data and association meta-data. Lastly, the document is parsed by customized scripts to normalize, validate, annotate, and store the publication, variant, and association data in the relational database [33]. Collected AD variants and association records are further linked (using positional and variant and gene identifier information) with the NIAGADS Alzheimer's Genomics Database [24] which provides the comprehensive annotation and functional genomic information. **Supplementary Note 2** provides details on ADVP architecture and implementation.

2.3 Meta-data schema for systematic curation and harmonization of genetic associations (Meta-data design)

2.3.1 Publication meta-data

Meta-data for all curated publications in ADVP was extracted from PubMed

(https://pubmed.ncbi.nlm.nih.gov) using the NCBI EDirect service

(https://www.ncbi.nlm.nih.gov/books/NBK179288) with publication PubMed identifiers

(PMID) as query keys. For each publication, we record its PMID, PubMed Central

identifier (PMCID), first and last authors, journal, and year of publications. We also store

the abstract, article URLs, and information on curated/source tables in the Publication

meta-data (**Figure 1**).

2.3.2 Association meta-data

ADVP association meta-data consists of 28 data fields, of which 19 are extracted

directly from the paper contents. The rest are harmonized (based on extracted original

information) and programmatically generated fields. Altogether, association meta-data

provide 1) variant information (Section "**2.3.2.1 Description of Variants**"); 2)

association information (Section "**2.3.2.2 Description of association records"**); and 3)

annotation information (Section "**2.4 Annotation of genetic variants and**

associations"). For a detailed explanation of these curated and harmonized/derived

data fields, see **Supplementary Table S2**.

2.3.2.1 Description of Variants

Each genetic variant in ADVP is described using dbSNP rsID, genomic coordinates

(chromosome:basepair), reference and alternative alleles. Both the information reported

in the publication (if available) and those derived from the reference databases such as

dbSNP [25] and NIAGADS Alzheimer's Genomics database [24], are included in the

variant description. Genomic location in ADVP is currently stored using GRCh37/hg19

reference genome build as the majority of GWAS publications conducted analyses

using GRCh37/hg19.

2.3.2.2 Description of association records

The primary association information was systematically extracted from each source

table and recorded as part of the ADVP association record. The extracted information

was further recoded and categorized, so that association records are described

consistently across publications. For each reported association we first collected a pre-

defined set of data attributes commonly reported by genetic association studies (See

"Extracted" columns under **Supplementary Table S2**). These include *p*-value and

statistics related to the effect size (regression beta coefficients and variance, odds

ratios, confidence intervals), reported effect allele and its frequency in the studied

population.

In addition to the information directly extracted from publications, each association in

ADVP is described with the nine harmonized meta-information data fields (see

Supplementary Note 1 for more details on each of these fields; field names are

denoted with the double quotes below):

1. "Record type": association record type.

2. "Population": normalized study population information.

3. "Cohort": normalized cohort names.

4. "Sample size": original sample size.

5. "Subset analyzed": description of the subset of samples used to perform the

association analysis.

6. "Phenotype": the outcome variable (phenotype/trait) of the association analysis.

7. "Association Type": standardized type of association (disease-risk, eQTL,

endophenotype, and others).

8. "Stage": analysis stage (discovery, validation, replication, or meta- or joint-

analysis). Please see (**Supplementary Figure 1, Supplementary Note 1**) for

details on how this information was derived.

9. "Imputation": imputation panel information.

Note, "Population", "Cohort", and "Phenotype" information are displayed in ADVP using

both the original (reported) and the derived, harmonized data fields.

221 2.4 Functional genomics evidence for genetic variants and associations

222 (Annotation)

All variants and association in ADVP were systematically annotated with genomic

context (closest upstream/downstream genes), genomic element (promoter, UTR,

intron, exon, intergenic, repeat), functional impact (variant most severe consequence),

and cross-referenced to NIAGADS Alzheimer's Genomics database [24].

ADVP reports the genomic context of each genetic variant via multiple data fields: 1)

"Locus" – records the gene name as reported in the publication; 2) "Nearest gene" –

contains the name of the gene closest to the variant and the distance to the gene (in

base pairs (bps)) in upstream (+) or downstream (-) orientation. The nearest genes are

identified using GENCODE v34 [26] protein-coding gene annotations. For each genetic

variant co-localized with one or more genes, both EnsemblID [27] and HGNC [28]

symbols for the gene(s) are reported. For each ADVP variant, the co-localized genomic

element is reported based on the genomic partition information [29,30].

2.5 Variant and association data verification (Quality control steps)

Quality control for the variant and association information in ADVP is carried out at

multiple levels:

1. We ensured records are not double-counted/re-reported across studies. Each

association record in ADVP is uniquely identified by a combination of reported

gene/SNP/interaction name, cohort/analyzed subset, association model used,

phenotype, and association p-value and effect size.

2. We cross-checked recorded positional information (chromosome:basepair), rsID,

and allele information against reference databases including, dbSNP [25],

NIAGADS Alzheimer's Genomics database [24], 1000 Genome data [31] to

ensure variant information is correct.

3. We identified and removed records solely representing associations annotated

by publicly available resources such as GTEx [32].

2.6 Population-based analysis of AD associations

To understand the genetic architecture of AD associated loci across populations, we

compared their reported effect sizes and frequencies for each locus. In this analysis, we

used all association records (from case-control GWAS studies) with complete

information on reported allele, effect size (odds ratio), and allele frequency. We then

analyzed the four major populations with the most association records (African

American, Asian, Caribbean Hispanic, and Caucasian/Non-Hispanic White). Any

association records with $p>0.01$ were excluded from analysis. Then for each AD-

associated locus (identified using the nearest gene), we selected the association record

with the most significant (smallest) p-value as a representative record for the locus.

To perform comparison, we normalized the original (reported) odds ratios to reflect the

effect of the minor allele. We further categorized the AD-associated loci as population-

specific or shared if they were associated with AD in more than one population under

study. We then compared AD-associated loci (both shared and population-specific)

across populations based on their normalized effect sizes (odds ratios for minor alleles)

and the minor allele frequency.

2.7 Functional analysis of AD associations

To perform functional analysis of the variants in ADVP, we evaluated the significance of

overlaps between ADVP variants and active enhancer elements across tissues and cell

types. We used Roadmap Epigenomics [33] (ChromHMM-determined [34]) and

FANTOM5 [35] enhancer sets across 35 tissue/cell type categories. We then ranked

individual tissue/cell types based on the degree and significance (odds ratio, Fisher's

exact test) of enhancer overlaps in each of the analyzed tissues/cell types.

3. Results

In terms of the number of curated AD-related associations and publications, ADVP is more comprehensive than the NHGRI-EBI GWAS catalog [23] (**Table 1**), the premier general catalog of published GWAS results, and more recent than AlzGene [36], another major database of published AD genetic association studies. In order to focus on association findings with the highest confidence, we decided to concentrate on large-scale association studies at the genomic level, with the majority of studies included in ADVP (65%) reporting associations reaching genome-wide significance, a gold standard for human genetic discoveries. Furthermore, ADVP collected extensive meta-data, including consortiums and cohorts, which were not available in the other two databases and are important for relating the results reported across publications. Finally, ADVP provides convenient links for investigators to explore biological significance of the reported variants (e.g., their genomic context, available functional genomic data or other known associations, if any) via an annotation in NIAGADS Alzheimer's Genomics database [24] (**Figure 1**). Following the ADVP curation criteria (see "**Data collection**", **Figure 1**), we first identified and screened 205 AD-related publications from 2009-2019. Out of these, we identified 125 publications with genetic associations reported in the main text tables (N=225 tables). Genetic variant and association data were then systematically extracted (Section "**2.2 Data extraction**"), harmonized ("**2.3 Meta-data design**") (converted into standard variant/association descriptors), annotated ("**2.4 Annotation**"), subjected to quality control steps ("**2.5 Quality control steps**") and stored in ADVP (**Figure 1**).

3.1 ADVP data summary

The ADVP V1.0 release contains high-quality genome-wide and suggestive AD-related genetic associations extracted from GWAS publications. This includes 6,990 genetic associations for variants, genes, and SNP interactions. **Figure 2** shows the distribution of ADVP genetic associations by harmonized meta-information data fields: a) Nine harmonized phenotypes; b) Six harmonized analyses type; c) Population, and d) Cohorts/Consortiums.

All ADVP association records are uniquely standardized into different categories:

1. As shown in **Figure 2A**, ADVP records are associated with nine different phenotype categories, with roughly half of them related to AD diagnosis. 15% of the records are related to fluid biomarkers, 7% with imaging and 6% with cognitive measures.

2. With respect to analysis type categories, ADVP includes 3,199 (45.8%) association records reported in disease-risk analyses, of which 1,342 and 934 associations are reported by meta- and joint-analyses, respectively. 1,887 (26.9%) of the records are related to AD endophenotype and 924 (13.2%) eQTL AD associations (**Figure 2B**).

3. ADVP is the first to collect AD genetic associations at SNP level (6,437, 92.1%), gene level (320, 4.5%), as well as SNP and gene interactions (233, 3.3%).

4. ADVP records present analyses results from seven populations as well as those from multi-ethnic analyses. ~88% of the records are for Caucasian (**Figure 2C**).

Others include African American, Arab, Asian, Caribbean Hispanic, Hispanic and

Non-Hispanic Caucasian.

5. ADVP records span analyses results published by ADGC using over 80 cohorts

(**Figure 2D**), including ADGC, Alzheimer's Disease Neuroimaging Initiative

(ADNI), Cohorts for Heart and Aging Research in Genomic Epidemiology

(CHARGE) Consortium, European Association of Development Research and

Training Institutes (EADI), European Network for Genetic and Genomic

Epidemiology (ENGAGE) Consortium, Enhancing NeuroImaging Genetics

through Meta-Analysis (ENIGMA) Consortium, The International Genomics of

Alzheimer's Project (IGAP) and others. See **Supplementary Table S3** for details

on cohorts included in ADVP.

Furthermore, ADVP provides annotation information for each genetic association

(Section "**2.4 Annotation**"). In summary, all the genetic association records in ADVP

were represented by >1,800 unique variants (based on genomic position) and >900

genomic loci (based on computed normalization). ADVP associations are mostly located

in non-coding regions including intronic (52.9%), intergenic (15.2%), and promoter

(5.9%) (**Figure 3A**). ADVP records are also cross-referenced to NIAGADS Alzheimer's

Genomics database [24]. **Figure 3B** summaries genetic variants in ADVP by functional

impact as determined by ADSP functional annotation pipeline [24,37,38] that uses VEP

effect predictor with customized ranking to generate most damaging consequence for

each variant [38].

3.2 ADVP features – search, browse and visualize

ADVP aims to provide a simple and unified resource to the scientific community,

allowing investigators to search and browse AD genetic association information more

easily. This is first done by displaying association records using a pre-selected set of

most important data fields (Section "**2.3.2.2 Description of association records**").

Investigators can further select additional data fields via the column selector (**Figure**

4A). All records are integrated with the NIAGADS Alzheimer's Genomics database,

allowing investigators to explore various kinds of biological annotations (e.g., CADD

score (Rentzsch et al., 2019)) and functional genomics evidence, including overlaps

with FANTOM5 [35], ENCODE histone modification [40], and gene ontologies from

KEGG [41] and UniProt [42].

The ADVP search interface was designed based on focus group use cases. ADVP

provides several ways to search for genetic association records:

1. By publication – investigators can quickly identify and retrieve all association

   records curated by ADVP for a particular study using PMID, PMCID, first or last

   author names, year of publication or article title

   (https://advp.niagads.org/publications).

2. By variant or gene of interest – investigators can search for the variant

   (https://advp.niagads.org/variants) or gene (https://advp.niagads.org/genes) of

   interest and browse all the associated ADVP records. Additionally, investigators

   can easily discover top variants or a gene with most association records or most

publications via the summary counts for association records and papers (**Figure**

4B, 4C).

3. By region of interest – investigators can search and retrieve all genetic

associations within the genomic regions of interest

(https://advp.niagads.org/search).

4. By integrative genome-wide plots – investigators can navigate the landscape of

AD genetics associations using the interactive chromosome ideogram

(https://advp.niagads.org/ideogram, **Figure 4D**) or interactive

population/phenotype variant viewer (https://advp.niagads.org/plot, **Figure 4E**).

Additionally, for each variant or gene, users can view the biological annotations and

functional evidence (e.g., 1000 Genomes project [31], dnSNP [25], GTEx [32],

ENCODE [40] and others) via the NIAGADS Alzheimer's Genomics database [24]

(**Figure 4F**).

3.3 ADVP use cases

ADVP is designed for various use cases in mind. First, ADVP can serve as a point of

entry for investigators to explore the AD genetics literature. They can browse through

variant and gene records, identify top associated loci for particular populations and

phenotypes, or inspect top GWAS associations in the gene or genomic region of

interest. Second, investigators can use ADVP to check their association analysis

findings. They can further restrict the comparison by focusing on results from a specific

population, cohort, or by comparing the strength of associations via p-values or

phenotypes. Lastly, investigators can use ADVP to check if their findings have

functional support from eQTL or other functional evidence collected in the NIAGADS

Alzheimer's genomics database (**Figure 4F**).

3.4. Genetic architecture of AD-associated loci across populations

To show the diversity and breadth of ADVP data, we performed population-based

analysis of AD associations in ADVP (Section **"2.6 Population-based analysis of AD**

associations"). Across four major populations (African American, Asian, Caribbean

Hispanic, Caucasian/Non-Hispanic white) with the most association records, 91 loci

(Section "**2.6 Population-based analysis of AD associations"**) were identified in any

of these 4 populations, whereas 10 of them were found in two or more populations,

including *BIN1*, *CD33*, *PICALM*, *SORL1*, and *ABCA7*. The majority of AD loci

(81/91=89%) were population-specific, i.e. found in only one population. This could

partially be explained by the underlying genetic differences across populations, but

could also be contributed by variability in GWAS sample sizes across

studies/populations, which could lead to the observed differences in association

strength and heterogeneity of loci identified in each population. Across the four

populations, the corresponding top SNP (Section "**2.6 Population-based analysis of**

AD associations"), effect size and allele frequency on all these 91 loci are available in

Supplementary Table S4.

We next explored the effect size and allele frequency of all AD-associated loci that are

found in any populations (**Figure 5A**), or those that are found in two or more

populations (shared AD loci) (**Figure 5B**).

As can be seen from **Figure 5**, ADVP captures reported AD-associated loci across

many populations (**Figure 5A**; only non-*APOE* loci from 4 populations are shown).

ADVP contains both population-specific AD loci and loci that are shared across

populations. As shown in **Figure 5B**, the shared loci tend to preserve their risk (e.g.,

ABCA7 [43]) and protective roles (e.g., *PICALM* [44]) .

On the other hand, as shown in **Figure 5A**, common loci tend to exert smaller effects

compared to population-specific loci, yet these effects of the common loci vary across

populations (**Figure 5B**) (i.e. are population-specific).

3.5. Functional analysis of ADVP variants

We next investigated the functional impact of ADVP variants. To do so, we analyzed all

ADVP variants that are associated with AD/ADRD (excluding eQTLs) in the Caucasian

or non-Hispanic White populations. A total of 1,675 ADVP variants met these criteria

and were analyzed.

First, to determine the potential causal genes for these variants, we asked if these

variants regulate any genes in any AMP-AD [45] eQTL data [46] obtained from three

different brain regions (dorsolateral prefrontal cortex, cerebellum and temporal cortex).

Please see this publication [46] for details of how these data eQTL was harmonized and

processed.

31% of the analyzed ADVP variants were identified as significant eQTLs in at least one

of the three AMP-AD eQTL datasets (FDR<0.01), and 32% among these were eQTLs in

all three brain regions. Altogether, these variants targeted 130 genes (including HLA

region), of which 31 were also the nearest genes reported in ADVP. These target genes

(e.g., *ACE, PVR*) were enriched in cell junction organization [47], and acetyltransferase

activity (cholinergic system) [48], which recapitulated some of the molecular and cellular

mechanisms underlying the pathogenesis of AD.

Second, we analyzed and ranked relevant tissue categories implicated by ADVP

variants. To do so, we quantified the significance and enrichment of tissue-specific

enhancer overlaps with ADVP variants (Section "**2.7 Functional analysis of AD**

associations"). The ADVP variants were enriched in regulatory elements profiled by

FANTOM5 and Roadmap Epigenomics (ChromHMM). Top tissues enriched in overlaps

between ADVP variants and Roadmap enhancers included AD-relevant blood

(OR=3.7), digestive (OR=3.5), brain (OR=2.8), and skeletal (OR=2.6) tissue categories.

The overlaps between ADVP variants and enhancers were shown to be enriched in

tissues known to be related to AD in various ways [49–55]. For instance, the implicated

immunity-related blood category is in line with recent work highlighting the role of

neuroinflammation in AD pathogenesis and etiology [49,55]. Digestive is related to the

gut microbiome, which can be linked to AD behavior in mice [56]. The implicated

skeletal category has also been previously linked with brain atrophy in AD [51].

In summary, analyses of genetic associations in ADVP revealed potential functional

roles of the AD variants in relevant tissue/cell type context, and recapitulated some of

the known regulatory mechanisms underlying AD pathogenesis.

461 **4. Discussion**

Here, we present ADVP, a portal to search, browse and visualize the largest collection

of systematically curated, harmonized, and annotated AD-specific genetic variants and

associations (~7,000 genetic associations in the current V1.0 release, November 2020).

Among the main distinctive features of ADVP is the uniqueness of reporting harmonized

AD variant and association information (standardized meta-table curation schema),

integration with the genomic annotation, and functional information (NIAGADS

Alzheimer's Genomics database [24]), as well as extensive cohort/consortium level

information.

ADVP uniquely includes associations at SNP, gene, and interaction levels and contains

curated phenotypes not limited to disease risk, but also includes endophenotypes, fluid

biomarkers, imaging, neuropathology, and other phenotypes. Moreover, ADVP curates

and records AD and ADRD eQTL association findings (**Figure 2B**).

In addition to the standard p-values and effect sizes reported for association records,

ADVP puts particular emphasis on harmonizing meta-data curated from the

publications. Both the curated and derived columns are stored in the database. These

include phenotype, association type, standardized gene names, study information

(population, cohort, sample size, subset analyzed), and details of analyses (analyses

type, imputation) (**Figure 4A**). All these columns enable the investigators to interpret,

compare and view these records at different levels: phenotype (**Figure 2A**), population

(**Figure 2C**), cohort (**Figure 2D**), to name a few.

All ADVP records are annotated with the genomic context (upstream/downstream

genes, and their distances) and their co-localized genomic element (**Figure 3**). They are

also cross-referenced with NIAGADS Alzheimer's Genomics DB [24], providing other

genomic annotation and functional genomic information. The standardized, structured

design of ADVP association data allows systematic integration with other genetic,

genomics, and molecular databases.

Population-based and functional analyses of AD associations revealed the genetic

architecture of AD-associated loci and points to tissue-specific regulatory mechanisms

for AD. However, variability in GWAS sample sizes may contribute to the observed

differences in associations and loci across different populations. Broadening the ADVP

coverage of population groups, as well as expanding functional data types and

coverage will provide further insights in complex genetic architecture and biology

underlying AD.

Lastly, we made substantial efforts to ensure high-quality of ADVP data contents. First,

quality control at multiple levels is performed (**Figure 1**, Section "**2.5 Quality control**

steps") to ensure the uniqueness of included genetic associations (no double counting /

re-reporting of associations). Besides, variant information in ADVP has been cross-

checked against other reference databases such as dbSNP.

ADVP will continuously be updated with versioned releases every six months. New

publications on AD-related GWASs and corresponding associations will be added in an

ongoing manner.

In the future, ADVP data collections will consist of a broader range of genetic results:

1. AD whole-genome/whole-exome sequencing analyses

2. AD xQTL associations, where x = protein, methylation, epigenetics marks, or

other molecular traits Other genetic variant types, such as insertions/deletions

(indel), copy number variations (CNV), or structural variations (SV) as they

become available

3. AD related dementias (ADRD) and neurodegenerative disorders

Future ADVP functionality will include further collection and addition of functional

genomic evidence supporting genetic associations.

To conclude, ADVP contains the largest collection of systematically curated,

harmonized, and annotated literature-derived variants for AD to the best of our

knowledge. The extensive and unique features in ADVP allow investigators to easily

access, interpret, compare, and visualize the vast collection of AD genetics findings.

5. Availability

All AD variant and association information is available through ADVP website (https://advp.niagads.org). The code for processing reported variant and association data is available upon request.

6. Acknowledgement

The authors thank Laura Cantwell, Lauren Kleidermacher, and Mitchell Tang for their contributions at various stages of this work. This work was supported by the National Institute on Aging [U24-AG041689, U54-AG052427, U01-AG032984, U01AG058654]; Biomarkers Across Neurodegenerative Diseases (BAND 3) (award number 18062), co-funded by Michael J Fox Foundation, Alzheimer's Association, Alzheimer's Research UK and the Weston Brain institute.

7. Figures

Figure 1. ADVP study design. AD GWAS publications are first collected (Section **"2.1**

Data collection"), genetic variant and association data are then systematically

extracted (Section "**2.2 Data extraction**"), harmonized (Section "**2.3 Meta-data**

design"), annotated (Section "**2.4 Annotation**"), subjected to quality control steps

(Section "**2.5 Quality control steps**") and stored into ADVP.

551
552

Figure 2: Summary of genetic association records in ADVP by **A**) Phenotype, **B**) Association type, **C**) Population, and **D**) Cohort/Consortium.

A)　　　　　　　　　　　　　　　　　　　　　　　　　　**B)**

Figure 3: Summary of ADVP association records by genome annotation and most-

significant functional consequence. **A)** Genomic localization of ADVP variants within

mRNA, lncRNA, and repeat elements. Shown are proportion (%) of variants in each

genomic element category; **B)** Most-significant predicted variant impact. Impact for

variants is determined using ADSP functional annotation pipeline [38,57] and is

provided by NIAGADS Alzheimer's Genomics database [24]. The consequence for a

variant is predicted and ranked based on multiple criteria including genomic location of

a variant, genes, transcripts and protein sequences, biological type of transcript,

transcript support level and other factors.

A)

Showing 1 - 12 of 12 records

Reset Filters   Show/Hide Columns

Pubmed ID	Record type	SNP	Coordinates	Locus	Population	Cohort	Sample size	Subset Analyzed	Phenoty
30820047	SNP-based	rs75932628	6:41129252	TREM2	Non-Hispanic Caucasian	ADGC, CHARGE, EADI, GERAD	63,926	All	AD
30820047	SNP-based	rs75932628	6:41129252	TREM2	Non-Hispanic Caucasian	ADGC, CHARGE, EADI, GERAD	82,771	All	AD
23150908	SNP-based	rs75932628	6:41129252	TREM2	Caucasian	Cohort from Europe	113,600	All	AD
23150908	SNP-based	rs75932628	6:41129252	TREM2	Caucasian	Cohort from Europe	12,438	All	AD
23150908	SNP-based	rs75932628	6:41129252	TREM2	Caucasian	Cohort from Europe	4,786	All	AD
28714976	SNP-based	rs143332484	6:41129207	TREM2	Caucasian	CHARGE, EADI, GERAD	3,968	All	AD
28714976	SNP-based	rs75932628	6:41129252	TREM2	Caucasian	ADGC	14,884	All	AD
28714976	SNP-based	rs75932628	6:41129252	TREM2	Caucasian	ADGC, CHARGE, EADI, GERAD	30,018	All	AD
28714976	SNP-based	rs143332484	6:41129207	TREM2	Caucasian	ADGC, CHARGE, EADI, GERAD	33,786	All	AD
28714976	SNP-based	rs75932628	6:41129252	TREM2	Caucasian	CHARGE, EADI, GERAD	35,831	All	AD
28714976	SNP-based	rs143332484	6:41129207	TREM2	Caucasian	ADGC, CHARGE, EADI, GERAD	53,042	All	AD
28714976	SNP-based	rs75932628	6:41129252	TREM2	Caucasian	ADGC, CHARGE, EADI, GERAD	80,733	All	AD

Show/Hide Columns menu:
- Reported gene
- Interactions
- Population
- Population (detailed)
- Cohort
- Cohort (detailed)
- Sample size

Disease risk (rows 6–12)

« ‹ Page 1 of 1 › »   Show 20 ∨ records

575 B)

Variants

Sort by frequency

Showing 1 - 10 of 1826 records

Variant	Reported gene(s)	Location	View in Genomics	Association records	Papers
rs3865444	CD33	chr19:51727962	View	39	16
rs11136000	CLU; CUGBP2; PICALM	chr8:27464519	View	60	15
rs2075650	APOC1, APOC4, APOE, PV	chr19:45395619	View	43	15
rs11218343	PICALM; SORL1	chr11:121435587	View	27	13
rs3851179	CUGBP2; PICALM	chr11:85868640	View	50	13
rs6656401	CR1,CR2; CR1; CR1L; CR2	chr1:207692049	View	76	12
rs3818361	CR1; CUGBP2	chr1:207784968	View	43	11
rs157580	PVRL2, TOMM40; TOMM4	chr19:45395266	View	15	10
rs1476679	PILRA, PILRB; GATS; MSX.	chr7:100004446	View	131	9
rs405509	APOE, TOMM40; APOE	chr19:45408836	View	28	9

« ‹ Page 1 of 183 › »   Show 10 ∨ records

583   C)

592   D)

606   E)

Variant viewer by Population/Phenotype

Switch between 'Population', 'Phenotype' to view variants across populations, and phenotypes.

To highlight variants for a particular population/phenotype, click on the corresponding population/phenotype in the legend (clicking on a legend item will toggle between highlight and normal view).

Population Phenotype

Select Effect size axis:

Log ⦿
Linear ○

623   F)

6:41129207:C:T (rs143332484)
CCACAAGTTGTGCGTGCTGACCACAC/TGCTGGCATGGGCCCTTCTCTCCCAG
single-nucleotide variant

🛒 Add to Basket   ⭐ Add to Favorites

☑ **ADSP Variant** **WES** **WGS**

WGS Filter Status: PASS: pass in both GATK and ATLAS

WES Filter Status: PASS: pass in both GATK and ATLAS

More information: dbSNP Ensembl GTEx ExAC

Contents
▸ Genomic Context
▸ Population Frequencies
▸ Trait Associations
▸ Classification/Predicted Effects
▸ Functional Genomics

Figure 4 – ADVP interface. **A)** Association records table. The displayed information can

be customized via column/field selector and filtered using provided text and data filters;

B) Top variants curated in ADVP. Variants are displayed according to the number of

reporting publications by default; association records for variants and variant-related

publications can be quickly accessed; **C)** Top genes curated in ADVP. Genes are

ordered by the number of reporting publications by default; gene-related association

records and publications can be quickly accessed; **D)** Interactive chromosome

ideogram-based view of association data; **E)** Interactive variant viewer by population

and phenotype. Variants are arranged by their effect size (odds ratio; Y-axis) and allele

frequency (X-axis) and color-coded by population and phenotype; **F)** Integration with

NIAGADS AD Genomics database [24] providing additional biological information and

functional evidence (red rectangles).

648 **A)**

B)

 Figure 5. ADVP catalogs AD genetic associations across 8 populations (>80 cohorts).

 AD-associated loci (non-*APOE*) for four major populations (African American, Asian,

 Caribbean Hispanic, Caucasian/Non-Hispanic White) are shown in this figure. For each

 locus, shown are the allele frequency and odds ratio for the most significant variant

 located with the locus. ADVP data captures the diversity and population-specificity of

 AD-associated loci. **A)** Shown are loci associated with AD in each of the major

 populations (shared loci are colored black, population-specific loci are shown in blue).

 B) Shown are shared AD loci reported in two or more major populations.

662 **8. Tables**

663 **Table 1**: Comparison between ADVP and existing AD genetics database (AlzGene and

664 GWAS Catalog).

Features	AlzGene [36]	GWAS Catalog [23]	ADVP
Focus on AD	Yes	No	Yes
Types of genetic associations recorded / included	Variant only	Variant only	Variant, Gene, SNP-SNP and gene-gene interactions
Included associations (p-value cutoff)	Genome-wide significant only ($<5*10^{-8}$)	Genome-wide significant only ($<5*10^{-8}$)	Both genome-wide significant and suggestive associations
Number of curated AD GWAS publications (publication years)	41 (1998-2011)	69 (2007-current)	Initial set: 205; Curated set: 125 (2009-current)
Number of curated records/associations	264 genes	1,532 records (1,155 variants)	6,605 AD, 6,990 total association records (1,825 variants)
Genomic and functional genomic annotations	No	No	NIAGADS Alzheimer's Genomics database [24] annotations
Detailed / extensive meta-data	Population, cohort, sample size, phenotype	Population, sample size, stage, phenotype	Record type (SNP/gene-based), population, cohort, sample size, subset analyzed, phenotype, association type, stage, imputation
Last update date	2011	2021	2021

9. References

[1]   Association A. 2019 Alzheimer's disease facts and figures. Alzheimer's Dement 2019;15:321–87. https://doi.org/doi:10.1016/j.jalz.2019.01.010.

[2]   Gatz M, Pedersen NL, Berg S, Johansson B, Johansson K, Mortimer JA, et al. Heritability for Alzheimer's disease: The study of dementia in Swedish twins. Journals Gerontol - Ser A Biol Sci Med Sci 1997;52. https://doi.org/10.1093/gerona/52A.2.M117.

[3]   Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921–3. https://doi.org/10.1126/science.8346443.

[4]   Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011;16:903–7.

[5]   Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41:1094–9.

[6]   Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41:1088–93.

[7]   Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et

al. Genome-wide analysis of genetic loci associated with Alzheimer disease.

JAMA 2010;303:1832–40.

[8]   Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al.

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are

associated with Alzheimer's disease. Nat Genet 2011;43:429–35.

[9]   Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common

variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-

onset Alzheimer's disease. Nat Genet 2011;43:436–41.

[10] Naj AC, Schellenberg GD. Genomic variants, genes, and pathways of Alzheimer's

disease: An overview. Am J Med Genet B Neuropsychiatr Genet 2017;174:5–26.

[11] Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al.

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for

Alzheimer's disease. Nat Genet 2013;45:1452–8.

[12] Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic

meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and

implicates Ab, tau, immunity and lipid processing. Nat Genet 2019;51:414–30.

[13] Biffi A, Anderson CD, Desikan RS, Sabuncu M, Cortellini L, Schmansky N, et al.

Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol

2010;67:677–85.

[14] Kauwe JS, Bailey MH, Ridge PG, Perry R, Wadsworth ME, Hoyt KL, et al.

Genome-wide association study of CSF levels of 59 alzheimer's disease

candidate proteins: significant associations with proteins involved in amyloid

processing and inflammation. PLoS Genet 2014;10:e1004758.

[15] Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, et al. GWAS of

cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.

Neuron 2013;78:256–68.

[16] Barral S, Bird T, Goate A, Farlow MR, Diaz-Arrastia R, Bennett DA, et al.

Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated

with episodic memory. Neurology 2012;78:1464–71.

[17] Barral S, Cosentino S, Christensen K, Newman AB, Perls TT, Province MA, et al.

Common genetic variants on 6q24 associated with exceptional episodic memory

performance in the elderly. JAMA Neurol 2014;71:1514–9.

[18] Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ, et al.

Genome-wide association meta-analysis of neuropathologic features of

Alzheimer's disease and related dementias. PLoS Genet 2014;10:e1004606.

[19] Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al.

Genome-wide meta-analysis identifies new loci and functional pathways

influencing Alzheimer's disease risk. Nat Genet 2019;51:404–13.

[20] Cukier HN, Kunkle BW, Vardarajan BN, Rolati S, Hamilton-Nelson KL, Kohli MA,

et al. ABCA7 frameshift deletion associated with Alzheimer disease in African

Americans. Neurol Genet 2016;2:e79.

[21]   Mez J, Chung J, Jun G, Kriegel J, Bourlas AP, Sherva R, et al. Two novel loci,

COBL and SLC10A2, for Alzheimer's disease in African Americans. Alzheimers

Dement 2017;13:119–29.

[22]   Hirano A, Ohara T, Takahashi A, Aoki M, Fuyuno Y, Ashikawa K, et al. A

genome-wide association study of late-onset Alzheimer's disease in a Japanese

population. Psychiatr Genet 2015;25:139–46.

[23]   Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al.

The NHGRI-EBI GWAS Catalog of published genome-wide association studies,

targeted arrays and summary statistics 2019. Nucleic Acids Res 2019;47:D1005–

12.

[24]   Greenfest-Allen E, Klamann C, Gangadharan P, Kuzma A, Leung YY, Valladares

O, et al. NIAGADS Alzheimer's GenomicsDB: A resource for exploring

Alzheimer's Disease genetic and genomic knowledge 2020.

https://doi.org/https://doi.org/10.1101/2020.09.23.310276.

[25]   Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP:

the NCBI database of genetic variation. Nucleic Acids Res 2001;29:308–11.

[26]   Frankish A, Diekhans M, Ferreira AM, Johnson R, Jungreis I, Loveland J, et al.

GENCODE reference annotation for the human and mouse genomes. Nucleic

Acids Res 2019;47:D766--D773.

[27] Yates AD, Achuthan P, Akanni W, Allen J, Allen J, Alvarez-Jarreta J, et al.

Ensembl 2020. Nucleic Acids Res 2020;48:D682--D688.

[28] Braschi B, Denny P, Gray K, Jones T, Seal R, Tweedie S, et al. Genenames.org:

The HGNC and VGNC resources in 2019. Nucleic Acids Res 2019;47:D786--

D792. https://doi.org/10.1093/nar/gky930.

[29] Amlie-Wolf A, Tang M, Mlynarski EE, Kuksa PP, Valladares O, Katanic Z, et al.

INFERNO: inferring the molecular mechanisms of noncoding genetic variants.

Nucleic Acids Res 2018;46:8740–53. https://doi.org/10.1093/nar/gky686.

[30] Kuksa PP, Lee C-Y, Amlie-Wolf A, Gangadharan P, Mlynarski EE, Chou Y-F, et

al. SparkINFERNO: A scalable high-throughput pipeline for inferring molecular

mechanisms of non-coding genetic variants. Bioinformatics 2020.

https://doi.org/10.1093/bioinformatics/btaa246.

[31] Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A

global reference for human genetic variation. Nature 2015;526:68–74.

[32] Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The

Genotype-Tissue Expression (GTEx) project. Nat Genet 2013;45:580–5.

https://doi.org/10.1038/ng.2653.

[33] Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, et al.

Integrative analysis of 111 reference human epigenomes. Nature 2015;518:317–

30. https://doi.org/10.1038/nature14248.

[34]   Ernst J, Kellis M. ChromHMM: Automating chromatin-state discovery and

characterization. Nat Methods 2012;9:215–6. https://doi.org/10.1038/nmeth.1906.

[35]   Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, et al.

An atlas of active enhancers across human cell types and tissues. Nature

2014;507:455–61. https://doi.org/10.1038/nature12787.

[36]   Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-

analyses of Alzheimer disease genetic association studies: the AlzGene

database. Nat Genet 2007;39:17–23.

[37]   Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for

annotating and predicting the effects of single nucleotide polymorphisms, SnpEff:

SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly

(Austin) 2012;6:80–92. https://doi.org/10.4161/fly.19695.

[38]   Butkiewicz M, Blue EE, Leung YY, Jian X, Marcora E, Renton AE, et al.

Functional annotation of genomic variants in studies of late-onset Alzheimer's

disease. Bioinformatics 2018;34:2724–31.

https://doi.org/10.1093/bioinformatics/bty177.

[39]   Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: Predicting the

deleteriousness of variants throughout the human genome. Nucleic Acids Res

2019;47:D886--D894. https://doi.org/10.1093/nar/gky1016.

[40]   Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, Doyle F, et al. An

integrated encyclopedia of DNA elements in the human genome. Nature

2012;489:57–74. https://doi.org/10.1038/nature11247.

[41]   Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a

793   reference resource for gene and protein annotation. Nucleic Acids Res

794   2016;44:D457--D462. https://doi.org/10.1093/nar/gkv1070.

795   [42]   Huntley RP, Sawford T, Mutowo-Meullenet P, Shypitsyna A, Bonilla C, Martin MJ,

796   et al. The GOA database: Gene Ontology annotation updates for 2015. Nucleic

797   Acids Res 2015;43:D1057--D1063. https://doi.org/10.1093/nar/gku1113.

798   [43]   Reitz C, Jun G, Naj A, Rajbhandary R, Vardarajan BN, Wang L-S, et al. Variants

799   in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk

800   of late-onset Alzheimer disease in African Americans. JAMA 2013;309:1483–92.

801   https://doi.org/10.1001/jama.2013.2973.

802   [44]   Thomas RS, Henson A, Gerrish A, Jones L, Williams J, Kidd EJ. Decreasing the

803   expression of PICALM reduces endocytosis and the activity of β-secretase:

804   implications for Alzheimer's disease. BMC Neurosci 2016;17:50.

805   https://doi.org/10.1186/s12868-016-0288-1.

806   [45]   Hodes RJ, Buckholtz N. Accelerating Medicines Partnership: Alzheimer's Disease

807   (AMP-AD) Knowledge Portal Aids Alzheimer's Drug Discovery through Open Data

808   Sharing. Expert Opin Ther Targets 2016;20:389–91.

809   https://doi.org/10.1517/14728222.2016.1135132.

810   [46]   Sieberts SK, Perumal TM, Carrasquillo MM, Allen M, Reddy JS, Hoffman GE, et

811   al. Large eQTL meta-analysis reveals differing patterns between cerebral cortical

and cerebellar brain regions. Sci Data 2020;7:340.

https://doi.org/10.1038/s41597-020-00642-8.

[47] Reymond N, Imbert A-M, Devilard E, Fabre S, Chabannon C, Xerri L, et al.

DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J

Exp Med 2004;199:1331–41. https://doi.org/10.1084/jem.20032206.

[48] Kehoe PG. The Coming of Age of the Angiotensin Hypothesis in Alzheimer's

Disease: Progress Toward Disease Prevention and Treatment? J Alzheimers Dis

2018;62:1443–66. https://doi.org/10.3233/JAD-171119.

[49] Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer's disease. Nat

Immunol 2015;16:229–36. https://doi.org/10.1038/ni.3102.

[50] Jiang C, Li G, Huang P, Liu Z, Zhao B. The Gut Microbiota and Alzheimer's

Disease. J Alzheimers Dis 2017;58:1–15. https://doi.org/10.3233/JAD-161141.

[51] Loskutova N, Honea RA, Vidoni ED, Brooks WM, Burns JM. Bone density and

brain atrophy in early Alzheimer's disease. J Alzheimers Dis 2009;18:777–85.

https://doi.org/10.3233/JAD-2009-1185.

[52] Wan Y-W, Al-Ouran R, Mangleburg CG, Perumal TM, Lee T V, Allison K, et al.

Meta-Analysis of the Alzheimer's Disease Human Brain Transcriptome and

Functional Dissection in Mouse Models. Cell Rep 2020;32:107908.

https://doi.org/10.1016/j.celrep.2020.107908.

[53] Amlie-Wolf A, Tang M, Way J, Dombroski B, Jiang M, Vrettos N, et al. Inferring

the Molecular Mechanisms of Noncoding Alzheimer's Disease-Associated

Genetic Variants. J Alzheimers Dis 2019;72:301–18. https://doi.org/10.3233/JAD-

190568.

[54]   Kikuchi M, Hara N, Hasegawa M, Miyashita A, Kuwano R, Ikeuchi T, et al.

Enhancer variants associated with Alzheimer's disease affect gene expression via

chromatin looping. BMC Med Genomics 2019;12:128.

https://doi.org/10.1186/s12920-019-0574-8.

[55]   Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J,

et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-

mediated innate immunity in Alzheimer's disease. Nat Genet 2017;49:1373–84.

https://doi.org/10.1038/ng.3916.

[56]   Kundu P, Torres ERS, Stagaman K, Kasschau K, Okhovat M, Holden S, et al.

Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in

AppNL-G-F, AppNL-F, and wild type mice. Sci Rep 2021;11:4678.

https://doi.org/10.1038/s41598-021-83851-4.

[57]   McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The

Ensembl Variant Effect Predictor. Genome Biol 2016;17.

https://doi.org/10.1186/s13059-016-0974-4.